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Abstract
Background: The use of a severity score to help orientation decisions could improve the efficiency of care for
acute exacerbations of COPD (AECOPD). We previously developed a score (‘2008 score’, based on age, dyspnea
grade at steady state and number of clinical signs of severity) predicting in-hospital mortality in patients with
AECOPD visiting emergency departments (EDs). External validity of this score remained to be assessed.
Objectives: To test the predictive properties of the ‘2008 score’ in a population of patients hospitalized in medical
respiratory wards for AECOPD, and determine whether a new score specifically derived from this population would
differ from the previous score in terms of components or predictive performance.
Methods: Data from a cohort study in 1824 patients hospitalized in a medical ward for an AECOPD were analyzed. Patients
were categorized using the 2008 score and its predictive characteristics for in-hospital mortality rates were assessed. A new score
was developed using multivariate logistic regression modeling in a randomly selected derivation population sample followed
by testing in the remaining population (validation sample). Robustness of results was assessed by case-by-case validation.
Results: The 2008 score was characterized by a c-statistic at 0.77, a sensitivity of 69% and a specificity of 76% for
prediction of in-hospital mortality. The new score comprised the same variables plus major cardiac comorbidities and
was characterized by a c-statistic of 0.78, a sensitivity of 77% and specificity of 66%.
Conclusions: A score using simple clinical variables has robust properties for predicting the risk of in-hospital death
in patients hospitalized for AECOPD. Adding cardiac comorbidities to the original score increased its sensitivity while
decreasing its specificity.
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Introduction
Acute exacerbations of chronic obstructive pulmonary
disease (AECOPD) are major events in the long-term
course of the disease since their repetition is associated
with impaired lung function, health status and survival
and markedly increased health care costs [1]. On the
short-term, they impair often notably health status and
expose to risks of acute respiratory failure and death.
Home-based care has been shown to represent a valu-
able alternative for many patients visiting emergency de-
partments (EDs), allowing to avoid or shorten hospital
stays [2]. However, most patients with AECOPD visiting
EDs are hospitalized. In that context, assessing the
severity of AECOPD is mandatory to guide decisions of
orientation (home, hospital medical ward or intensive
care unit -ICU-) as well as intensity of monitoring, treat-
ment and follow-up during and after the acute episode
[3]. Knowledge of all relevant prognostic factors is of
major importance to determine the safest and most cost-
effective setting for patient care. Several scores (e.g., the
BAP-65 or DECAF scores) have been specifically devel-
oped to allow risk prediction in patients hospitalized for
acute exacerbations of COPD, and were shown to perform
better than scores primarily developed for other respira-
tory illnesses (i.e., community-acquired pneumonia) such
as CURB-65 [4,5]. However, studies in this area are het-
erogeneous in terms of measured variables. In addition,
some data (such as biomarkers) [6] might not be readily
available in all settings, underlining the need for simple,
purely clinical prediction rules. In other diseases such as
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community-acquired pneumonia, the use of scores (e.g.,
the Pneumonia Severity Index) was shown to improve the
efficiency of care by allowing to decrease hospitalization
rates without increasing the risk of poor outcome [7].
In 2003–2004, we conducted a prospective cohort study
of 794 patients with AECOPD recruited in 104 French
emergency departments [8]. Among these patients, only
10.5% were discharged home; in the remaining, the in-
hospital mortality rate was 7.4%. Independent predictors
of in-hospital death were age, clinical signs of severity and
baseline dyspnea grade at steady state. From these
observations, we derived and validated a prognostic score
(Table 1) using two randomly selected halves of the cohort
(the derivation and validation cohorts). For convenience,
this score will be subsequently called the ‘2008 score’ after
its year of publication. Its discriminative capacity proved
to be satisfactory with a c-statistic (which is analogous to
the area under the receiver operating characteristic -ROC-
curve) at 0.82 in the validation cohort. Therefore, we
aimed at assessing the validity of the 2008 score in another
cohort that was primarily built to assess the long-term
(4 years) prognosis and prognostic factors of patients hos-
pitalized in medical wards for an AECOPD [9]. Consider-
ing the marked differences in the mode of recruitment
(hospital wards vs EDs), study period, patients’ characteris-
tics and mortality rate (see Table 2) between the two co-
horts, we postulated that demonstrating a satisfactory
discriminative capacity of the 2008 score in this new co-
hort would allow to generalize its use.
We also questioned whether a new score developed
using data from patients of the new cohort would be
different and more accurate to predict prognosis than
the 2008 score. Thus, we applied the same methodology
as in the previous study to develop a new score before
comparing its components and performance to that of
the 2008 score.
Material and methods
Study design
Details on study design and collected data have been
published previously [9,10]. From October 2006 to June
2007, lung specialists from 68 French general hospitals
consecutively included 1,824 patients newly admitted in
their respiratory medicine department for an acute exacer-
bation of COPD, regardless of the source of admission
(i.e., direct referral or via emergency department, intensive
care unit [ICU], outpatient clinic, or another department
or hospital). To be selected patients had to satisfy four
conditions: (1) having or being strongly suspected of hav-
ing COPD; for the second category, i.e. those suspected of
Table 1 Calculation of the 2008 score
2008 score Points
Age
● < 70 years 0
● > = 70 years 1
MRC (baseline, steady state)
●0-1 0
●2-3 1
●4-5 2
Number of signs of severity* at entry
●0 0
●1-2 2
●3 and more 3
*signs of severity: cyanosis, use of accessory inspiratory muscles, paradoxical
abdominal movement, asterixis, neurological impairment, lower limb edema.
Total score ranges from 0 to 6. Tertiles of the original (2008) population
corresponded to scores of 0–1, 2–3 and 4–6, respectively.
Table 2 Main differences between the population in
which the 2008 score was developed and the present
population. All p ≤ 0.001
Variable Present
population
2008
population
Sex, % women 23.2 30.0
Age (years, mean ± SD ) 70.3 ± 11.3 72.5 ± 11.8
Smoking status, %
●Non smoker 6.6 19.3
●Ex smoker 60.8 49.9
●Smoker 32.6 30.8
MRC dyspnea grade at steady state, %
●0/1 17.1 22.5
●2-3 69.9 46.2
●4 13.0 31.3
Maintenance treatment, %
●LTOT 37.7 23.2
●Inhaled corticosteroids 72.4 43.8
●Oral corticosteroids 7.8 13.8
●Bronchodilators 86.6 69.6
Clinical signs of severity, %
●Cyanosis 22.1 29.0
●Use of accessory inspiratory muscles 27.9 50.9
●Paradoxical abdominal movement 8.6 36.8
●Asterixis 1.8 7.8
●Neurological impairment 6.9 11.8
●Lower limb edema 13.3 23.3
Number of clinical signs of severity, %
●None 44.1 27.6
●1 -2 45.9 47.7
●≥ 3 10.0 24.7
Mortality (%) 2.5 7.9
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having COPD, the diagnosis had to be confirmed subse-
quently by senior lung specialists during hospital stay;
(2) presenting with an acute increase in at least one car-
dinal respiratory symptom (cough, sputum production
or purulence, dyspnea) that was not immediately attrib-
utable to an alternative diagnosis such as pulmonary
edema, pulmonary embolism, etc.; and (3) presenting with
a condition considered sufficiently worrying in terms of dur-
ation and intensity to warrant hospitalization. All patients
were informed of the objectives and requirements of the
study and gave their oral consent before inclusion, as re-
quired by French regulation on observational studies. The
protocol was approved by the Ethics Committee of the
French-Language Society of Pulmonology.
Collected data
Collected data addressed the characteristics of (i) the
patient (i.e., anthropometric and sociodemographic char-
acteristics, medical history, habits); (ii) underlying COPD
(clinical characteristics, FEV1 and management before
the exacerbation); (iii) the acute exacerbation (etiology
and clinical characteristics on admission); (iv) hospital
care (admission modalities, care pathways, treatments
of the acute exacerbation) and (v) outcomes (duration
of hospital stay, vital status at discharge). Spirometry re-
sults used in the analyses were the most recent prior to
the exacerbation. Collected comorbidities of interest were
ischemic heart disease, left heart failure, pulmonary hyper-
tension, gastro-esophageal reflux, lung cancer, associated
respiratory diagnoses (asthma, bronchiectasis, sleep apnea
syndrome, obesity-hypoventilation syndrome).
Statistical analyses
Standard SAS® procedures (SAS Institute, Cary, NC,
USA) were used for statistical analysis. A description of
the population was performed for all variables. Character-
istics of this population were compared to that of the 2008
population using Chi2-test for categorical variables and
Student t test or analysis of variance (ANOVA) (normal
distribution) or non-parametric tests (non-normal dis-
tribution) for quantitative variables. The same methods
were used to analyze factors associated with in-hospital
death in the present population.
Two approaches were then used to test the validity of
the 2008 score: the first was its implementation in the
present population, allowing to calculate mortality rates
by score category and to assess its predictive properties;
the second was the development of a new score based
on the characteristics of the present population, to as-
sess whether this new score would be different from
the 2008 score in terms of components and predictive
performance.
Application of the 2008 score in the studied population
To assess the global predictive capacity of the 2008 score
in the present population, the score was calculated for
each patient and the population was divided into three
groups based on the scores observed in tertiles of the
2008 population (i.e., 0–1 for group 1, 2–3 for group 2
and 4 or more for group 3). Mortality rates were com-
pared between groups, and sensitivity and specificity of
the score for prediction of mortality was assessed. The
c-statistic, which is analogous to the area under the re-
ceiver operating characteristic (ROC) curve, was then
calculated.
Development of a new score
To develop the new score, we used data collected during
the first 24 hours of hospitalization in the studied popu-
lation (see above). Two methods were used: the first
(described below) was based on randomly selected der-
ivation and validation cohorts, as for the development
of the 2008 score, while the second (presented in the on-
line Additional file 1) used score derivation and case-by-
case validation in the whole population.
To implement the first method, the population was ran-
domly split into two groups: a derivation cohort (n = 912)
and a validation cohort (n = 912). In the derivation cohort,
a backward stepwise logistic regression procedure was
used, in which variables that were significant at p < 0.25 in
univariate analyses were introduced. This p-value thresh-
old was chosen to ensure without any doubt that no rele-
vant variable would be missed: indeed, some variables that
were thought to be of potential clinical importance such
as coexisting asthma or sleep apnea syndrome were asso-
ciated with mortality with a p value of about 0.20 in uni-
variate analysis. Variables were eligible for inclusion in the
final model if they were significantly associated with death
at a two-tailed p-value of less than 0.05. As previously
described [11–13], the multivariate model then allowed
developing a point-based risk scoring system: the number
of points assigned to each risk factor was obtained by div-
iding each Beta coefficient by the smallest Beta coefficient
significantly different from 0 and rounding to the nearest
integer. A risk score was assigned to each participant
in both derivation and validation cohorts by summing
the number of points corresponding to each risk factor.
Model discrimination was assessed by the c statistic. In
both derivation and validation cohorts, subjects were
divided into three groups corresponding to tertiles of
the score in the whole population, and mortality rates
were compared between groups.
Results
Patients and in-hospital outcomes
Recruited patients reported recent acute and sustained
onset or increase in dyspnea in 95% of cases, cough in
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65% and sputum volume and/or purulence in 55%.
Table 2 shows the main characteristics of the 1,824 pa-
tients at entry, compared to the 2008 population. Age
was <60 years in 19.9% and ≥80 years in 23.2%.There
was no difference in cumulative smoking (43.5 ± 25.2 vs
46.4 ± 30.0 pack-years), percentage of patients complain-
ing of an increase in dyspnea (95.2% vs 99.2%) or of puru-
lent sputum (42.6% in each population), percentage of
patients in whom COPD had been previously diagnosed
(84.1% vs 84.6%). Only 6.6% of patients were never
smokers, 32.6% were still active smokers. Lung function
data were obtained for 1615 patients (88.9%), with a delay
of 17.4 ± 23.9 months between spirometry and hospital
admission for AECOPD. FEV1 was 45.6 ± 17.7 L/s, with
the following distribution of GOLD severity of airflow ob-
struction: GOLD I: 4.5%; GOLD II: 32.7%; GOLD III:
43.5%; GOLD IV: 19.4%. This could not be compared to
the 2008 population, in which lung function data were not
available in most cases in the context of the Emergency
Department setting. Comorbidities, which were not re-
corded in details in the 2008 population either, were fre-
quent in the present population: ischemic heart disease
(IHD): 19.0%, left heart failure (LHF): 12.7%, systemic
hypertension: 35.1%, asthma: 13%. BMI was ≤20 kg/m2 in
20.3% of patients and >25 kg/m2 in 45.1%.
In-hospital mortality rate was 2.46% (n = 45). Hospital
length of stay was12.1 ± 9.7 days, i.e., similar to what was
observed in the 2008 population (11.8 ± 14.1 days).
Application of the 2008 score
Patients were distributed in three groups based on their
2008 score. These groups were defined based on the
tertiles of the score in the original (2008) population.
Mortality rates are shown in Table 3, and Table 4 presents
the discriminative performance of the score, which was
characterized by a c-statistic at 0.77, with a sensitivity
of 69% and a specificity of 76%. In Tables 3 and 4, these
results are compared to that obtained with the new
score (see below).
Development of the new score
Variables associated with survival status at the end of
hospital stay in univariate analyses performed in the
whole studied population are presented in Additional
file 1: Tables S1 and S2. Among these, multivariate ana-
lyses in the derivation cohort identified age, number of
clinical signs of severity, mMRC dyspnea grade at steady
state and presence of cardio-vascular comorbidities
(ischemic heart disease and/or left heart failure) as being
independently associated with mortality (Table 5). Table 6
shows how the new score was calculated based on these
results. Mortality rates in the three tertiles of the score are
shown in Table 3 for the derivation and validation cohorts,
compared to those observed with the 2008 score in the
three groups of the whole studied population defined with
reference to distribution (i.e., tertiles) of this score in
the 2008 population. The discriminative performance of
the new score in the derivation and validation cohorts is
presented in Table 4, compared to that of the 2008
score. The c-statistics were at 0.79 and 0.78 in the deriv-
ation and validation cohorts, respectively, with a sensi-
tivity of 77% in both cohorts and specificities of 67%
and 66%, respectively. Results of the case-by-case devel-
opment and validation method were identical and are
presented in Additional file 1: Table S3.
Discussion
The initial score published in 2008 appears to have a
good overall performance in the population studied here,
as assessed by a similar discriminative performance (as
assessed using the c-statistic) as in the original (2008)
population. However, the 2008 score was less sensitive
(but more specific) for prediction of mortality than a
new score specifically derived from data of the studied
population and additionally integrating cardiac comor-
bidities (which were not consistently recorded in the
original −2008- population). Therefore, since the main
purpose of such score should be to identify as much at-
risk patients as possible, the new version might be pref-
erable, at least for a population of patients hospitalized
in a medical ward for an acute COPD exacerbation.
Strengths and limitations, applicability of results
One important strength of this study is that collected
data were those usually available immediately at presen-
tation in patients with exacerbations of COPD, to ensure
Table 3 Mortality rates by categories of the 2008 score and the new score
2008 score New score
Categories Groups* Deaths n (%) Tertiles Deaths n (%)
Derivation cohort Validation cohort
0-1 point 692 (37.9%) 5 (0.7%) 0 point 1 (0.3%) 0 (0%)
2-3 points 672 (36.8%) 11 (1.6%) 1-2 points 4 (1.3%) 5 (1.6%)
4-6 points 460 (25.2%) 29 (6.3%) 3-9 points 18 (5.8%) 17 (5.5%)
*defined with reference to the distribution (i.e., tertiles) of the 2008 score in the 2008 population.
The new score was built using data collected in the studied population.
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that the study conditions reflected what happens in the
real-life. Actually, FEV1 or arterial blood gas tensions
did not add anything to the purely clinical variables that
constituted both the 2008 score and the new score. We
did not include any biomarker in the assessment of stud-
ied patients, since these variables might not be available
in all settings yet nor immediately at patients’ entry,
which could limit the generalizability of a score relying
on them. Indeed, variables of interest were collected ra-
ther exhaustively; however, this would have been quite
different outside of a clinical survey (see below). Most
scores developed in patients with AECOPD actually rely
on some biological variables [4,5]. Even if these variables
are available in most settings, this may increase the delay
between arrival in the ED and risk stratification and,
therefore, decisions regarding patients’ orientation. An-
other strength is that two methods of development and
validation of the new score were used, with identical
results. This is reassuring as to the robustness of this
score.
Some limitations also have to be considered when
interpreting the results. Firstly, this study was performed
in patients admitted to a medical respiratory ward for
AECOPD, whatever their care pathway had been before.
Therefore, although these patients were otherwise unse-
lected, they are not representative of patients visiting
Emergency Departments of admitted in Intensive Care
Units or in non-specialized (e.g., internal medicine) wards.
Indeed, the main purpose of these analyses was not to
build a new score to be applied in a specific population,
but to determine whether a score originally developed in
patients visiting EDs could be applied in other settings
with satisfactory properties. Secondly, patients recruited in
a medical ward are by nature those who have survived the
first step of care for their exacerbation, e.g. the ED care.
Indeed, in our 2008 study, 10 patients died in the ED
(1.25%) and 7 (0.9%) died in the ICU in which they had
been transferred from the ED [9]. Overall, 28,8% of all in-
hospital deaths observed in that study occurred before the
patient could reach the medical ward, and would therefore
not have been captured in the present study.
Variables included in the 2008 score and the new score
Besides differences in the weighting of some variables,
the main difference between the two scores was that the
new one accounted for cardio-vascular major comorbidi-
ties, i.e., IHD and LHF. This is likely explained by the
lack of details on cardio-vascular comorbidities in the
2008 population, obviously preventing them from being
reliably included in the score calculation. All other con-
tributing variables (i.e., age, baseline mMRC grade at
steady state and number of clinical signs of severity at
entry) were the same, which confirms the strength of their
association with mortality. This underlines the major im-
portance of recording them at entry, which is not always
done. Indeed, an audit in UK hospitals found marked het-
erogeneity of variables recorded in patients hospitalized
for AECOPDs [14]. The European Respiratory Society
audit on AECOPDs also found noticeable discrepancies
between settings and countries in the way AECOPDs
are assessed and cared for [15]. Whether this translates
in differences in outcomes or cost-effectiveness of care
remains to be demonstrated.
Table 4 Performance of the scores in the present
population (95% CI)
2008 score New score
c-statistic 0.77 (0.72-0.81) 0.79 (0.74-0.82)
Sensitivity 0.64 (0.48-0.78) 0.77 (0.61-0.86)
Specificity 0.76 (0.74-0.78) 0.67 (0.65-0.69)
Table 5 Results of multiple logistic regression identifying
factors independently associated with mortality in the
studied population
Odds-Ratio 95% CI P value
Age (per year) 1,06 1,02-1,10 0,002
mMRC grade > 2 vs 0-1 3,91 1,70-8,96 0,001
Cardiovascular comorbidity
(IHD and/of LHF)
2,28 1,06-4,91 0,036
Clinical signs of severity during
the first 24 hours (per sign)*
1,34 1,18-1,53 <0,001
IHD : Ischemic heart disease; LHF: Left heart failure. *among the following: use
of accessory inspiratory muscles, asterixis, neurological impairment,
paradoxical abdominal movement, lower limb edema, cyanosis.
Table 6 Calculation of the new score, based on results of
multivariate analysis of factors associated with in-hospital
death in the studied population
New score Points
Age
● < 60 years 0
●60-80 years 1
●80 years 2
MRC (baseline, steady state)
●0-2 0
● > 2 3
Cardiovascular disease
●No 0
●Yes 2
Number of signs of severity (first 24 hours)
●0 0
●1-2 1
●3 and more 2
Range of the total score: 0–9.
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Interestingly, the importance of cardio-vascular comor-
bidities as prognostic factors in AECOPD is in line with
the high proportion of cardiovascular deaths in patients
with COPD [16,17]. Indeed, cardiovascular comorbidities
are frequent in these patients [18,19], due to common risk
factors (smoking, age) and maybe also to specific patho-
physiological mechanisms involving COPD-associated
systemic inflammation [20–22]. COPD is also known
to impair the prognosis of cardiovascular diseases such
as IHD or CHF [23,24] while a low FEV1 increases the
risk of atheroma [25] and cardiovascular death [26]. In
addition, ischemic cardiovascular events are frequent
during and early after AECOPD [27,28].
Is the use of a score able to improve outcomes of
AECOPD?
In the field of AECOPD outside ICUs, it has never been
demonstrated that using such a score has an effect on
the appropriateness of medical decisions. In other acute
respiratory diseases such as community acquired pneumo-
nia (CAP), the use of scores (e.g. the Pneumonia Severity
Index) was shown to improve the efficiency of patients
orientation through a decrease in hospitalizations without
any increase in the risk of poor outcome [7]. However, it
might be argued that AECOPD and CAP are conceptually
very different diseases: CAP are by definition of infectious
origin while only about 50% of AECOPD are associated
with identification of a pathogen [1]. In AECOPD, the
main phenomenon is not parenchymal infection but air-
ways obstruction. In addition, in AECOPD other etiolo-
gies of respiratory failure such as pulmonary embolism
are frequent and frequently undiagnosed [29]. Thus, it
could be hypothesized that building a simple clinical
score would be more difficult in AECOPD, due to their
marked heterogeneity. However, the scores we developed
are not more complex than, e.g., the CRB-65. Conversely,
in a recent study, Steer et al. developed a score called the
DECAF score, relying on extended MRC Dyspnoea Score,
eosinopenia, consolidation, acidaemia, and atrial fibril-
lation [5]. Using internal bootstrap validation, the score
predicted mortality quite reliably, with an area under
the receiver operator characteristic (ROC) curve of 0.86.
In addition, the DECAF score was a significantly stronger
predictor of mortality than CURB-65. However, this score
relies not only on clinical features but also on some
radiological and biological characteristics, which might
limit its applicability for use at entry in the ED. Besides
the variables included in these scores, several other clin-
ical, biological or radiological data have been found to
be of prognostic significance in AECOPD (regarding, e.g.,
the risks of death, need for mechanical ventilation or
prolonged hospitalization) [3]. Adding biological or im-
aging variables might improve the predictive capacity of
the scoring systems but, as mentioned above, this would
compromise their use in the community setting and,
even in the hospital, awaiting their results could delay
the score-based decisions.
Interestingly, although the DECAF score comprises
three non-clinical (i.e., biological or radiological) variables,
the area under the ROC curve (0.86) in its development
study was not considerably superior to that of our purely
clinical score (0.79). Of note, the c-statistic of the BAP-65
score (which uses one biological variable, BUN) in the
validation study by Shorr et al. was also 0.79 [30].
Conclusions
In this study, we confirm in hospitalized patients the
overall good predictive properties of a purely clinical
score initially developed in patients visiting the ED for
an AECOPD. Adding major cardiac comorbidities (IHD,
LHF) to scoring items increased the sensitivity of the
score for mortality prediction. Additional studies are
required to determine whether the use of such scores
increases the efficiency of care for AECOPD, both in
hospital or community settings.
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